DOCSLIB.ORG

The Role of Angiogenesis in Hepatocellular Carcinoma Michael A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of Angiogenesis in Hepatocellular Carcinoma Michael A Published OnlineFirst October 1, 2018; DOI: 10.1158/1078-0432.CCR-18-1254 Review Clinical Cancer Research The Role of Angiogenesis in Hepatocellular Carcinoma Michael A. Morse1, Weijing Sun2, Richard Kim3, Aiwu Ruth He4, Paolo B. Abada5, Michelle Mynderse6, and Richard S. Finn7 Abstract Hepatocellular carcinoma (HCC) accounts for about 90% systemic treatments such as those targeting the vascular endo- of all primary liver cancers and is the second leading cause of thelial growth factor receptor and its ligand. However, the cancer-related deaths worldwide. The hypervascular nature of clinical relevance of other more recently identified angiogenic most HCC tumors underlines the importance of angiogenesis pathways in HCC pathogenesis or treatment remains unclear. in the pathobiology of these tumors. Several angiogenic path- Research into molecular profiles and validation of prognostic ways have been identified as being dysregulated in HCC, or predictive biomarkers will be required to identify the patient suggesting they may be involved in the development and subsets most likely to experience meaningful benefit from this pathogenesis of HCC. These data provide practical targets for important class of agents. Clin Cancer Res; 1–9. Ó2018 AACR. Introduction Angiogenesis and Angiogenic Targets in Hepatocellular carcinoma (HCC) is the second leading Advanced HCC cause of cancer mortality (1). Most patients with HCC present Hypoxia is presumed to robustly stimulate tumor angiogenesis with advanced disease (2), and the 5-year overall survival (OS) (17, 18). Several animal models examining the hypoxic tumor rates are 10% for locally advanced and 3% for metastatic microenvironment in HCC with small fiberoptic sensors or radio- disease (3). Although HCC follows diverse causes of liver graphic imaging with oxygen-sensitive probes have shown intra- damage (including chronic alcohol use, chronic hepatitis B tumor oxygen values that were significantly lower than those in and C infection, and nonalcoholic fatty liver disease; ref. 4), normal liver tissue (18–20). Direct evidence of hypoxia in human fi common associated ndings are hypervascularity and marked HCC is sparse, and results have not been as clear (21). Most HCC vascular abnormalities (5), such as arterialization and sinu- in vitro and in vivo models investigating hypoxia-mediated soidal capillarization (6). Increased tumor vascularity may mechanisms in HCC focus on the upregulation of hypoxia-induc- result from sprouting angiogenesis or by recruiting existing ible factor proteins, which induce expression of proangiogenic vessels into the expanding tumor mass (a process called factors, including vascular endothelial growth factor (VEGF), that co-option). This review addresses the molecular underpinnings promote angiogenesis in HCC tumors (17, 18, 22, 23). At the of angiogenesis in advanced HCC, current approaches to molecular level, angiogenesis results from an imbalance between targeting angiogenesis (Table 1), novel strategies in develop- drivers of vessel growth and maturation [VEGF-A, -B, -C, and -D, ment, and prospects for combining antiangiogenic therapy fibroblast growth factors (FGF), platelet-derived growth factors with other systemic modalities. (PDGF), angiopoietins, hepatocyte growth factor, endoglin (CD105), and others] and inhibitors (angiostatin, endostatin, thrombospondin-1, and others). Proangiogenic factors activate endothelial cell tyrosine kinases and subsequent downstream intracellular signaling through mitogen-activated protein kinase 1 Department of Medicine, Division of Medical Oncology, Duke University Health and phosphatidylinositol-3-kinases (PI3K)/Akt/mTOR pathways System, Durham, North Carolina. 2Division of Medical Oncology, University of Kansas School of Medicine, Kansas City, Kansas. 3Department of Gastrointestinal leading to angiogenesis (24). The complexity and potential syn- Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ergism of these pathways that stimulate angiogenesis have 4Department of Medicine, Georgetown University Medical Center, Washington, prompted the development of multiple antiangiogenic therapies District of Columbia. 5Eli Lilly and Company, Indianapolis, Indiana. 6Syneos over the last several decades. 7 Health, Clinical Solutions, Raleigh, North Carolina. Department of Medicine, In fact, most currently approved treatments for advanced HCC Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Los in the first- and second-line settings target angiogenic pathways. Angeles, California. Of the known or potential angiogenic pathways in tumors, the Note: Current address for M. Mynderse: PRA Health Sciences, Raleigh, North VEGF/VEGF receptor (VEGFR) signaling pathway has been vali- Carolina. dated as a drug target in HCC (7, 14). The first breakthrough Corresponding Author: Michael A. Morse, Department of Medicine, Division of systemic therapy for treating advanced HCC was sorafenib (4), a Medical Oncology, Duke University Health System, Duke Box 3233, Durham, NC multikinase inhibitor that disrupts VEGFR signaling as well as 27710. Phone: 919-681-3480; E-mail: [email protected] several other targets involved in angiogenesis (ref. 7; Table 1). doi: 10.1158/1078-0432.CCR-18-1254 Other molecular pathways that may have angiogenic effects Ó2018 American Association for Cancer Research. are specifically targeted by several agents under investigation www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2018 American Association for Cancer Research. OF2 Clin Cancer Res; 2018 Morse et al. Downloaded from Table 1. Antiangiogenic therapies evaluated in phase III trials for treatment of HCC Published OnlineFirstOctober1,2018;DOI:10.1158/1078-0432.CCR-18-1254 mOS mPFS ORR DCR clincancerres.aacrjournals.org Compound Type Target(s) Phase Treatment line Regimen N (mos) HR (95% CI), P (mos) HR (95% CI), P (%) (%) Sorafenib (7) TKI VEGFR-1–3, PDGFR-b, III 1st line Sorafenib 299 10.7 0.69 (0.55–0.87), <0.001 5.5 0.58 (0.45–0.74), <0.001 2 43a c-Kit, FLT-3, RET, Raf- Placebo 303 7.9 2.8 1 32a 1, B-Raf Regorafenib (8) TKI VEGFR-1–3, PDGFR-b, III 2nd line Regorafenib 379 10.6 0.63 (0.50–0.79), <0.0001 3.1 0.46 (0.37–0.56), <0.0001 11b 65b,c FGFR1, CD117, RET, Placebo 194 7.8 1.5 4b 36b,c B-Raf, TIE2 Sunitinib (9) TKI VEGFR-1–3, PDGFR, III 1st line Sunitinib 530 7.9 1.30 (1.13–1.50), 0.0014 3.6 1.13 (0.99–1.30), 0.229 6.6 50.8d c-Kit, FLT-3, RET Sorafenib 544 10.2 3.0 6.1 51.5d Brivanib (10) TKI VEGFR, FGFR III 1st line Brivanib 577 9.5 1.07 (0.94–1.23), 0.312 4.2e 1.01 (0.88–1.16), 0.853 9b 65b Sorafenib 578 9.9 4.1e 12b 66b Brivanib (11) TKI VEGFR, FGFR III 2nd line Brivanib 263 9.4 0.89 (0.69–1.15), 0.331 4.2e 0.56 (0.42, 0.76), <0.001 10 61 Cancer Research. Placebo 132 8.2 2.7e 240 Linifanib (12) TKI VEGFR, PDGFR III 1st line Linifanib 514 9.1 1.05 (0.90–1.22), ns 5.4 0.76 (0.64–0.90), 0.001 13.0 NR on September 28, 2021. © 2018American Association for Sorafenib 521 9.8 4.0 6.9 NR Lenvatinib (13) TKI VEGFR-1–3, FGFR-1–4, III 1st line Lenvatinib 478 13.6 0.92 (0.79–1.06) 7.4 0.66 (0.57–0.77), <0.001 24.1b,f 75.5b,f PDGFR-a, RET, c-Kit Sorafenib 476 12.3 3.7 9.2b,f 60.5b,f Ramucirumab (14) IgG1 mAb VEGFR-2 III 2nd line Ramucirumab 283 9.2 0.87 (0.72–1.05), 0.14 2.8 0.63 (0.52–0.75), <0.0001 7.1 56.2 Placebo 282 7.6 2.1 0.7 45.7 Ramucirumab (15) IgG1 mAb VEGFR-2 III 2nd line; only patients Ramucirumab 197 8.5 0.71 (0.53–0.95), 0.0199 2.8 0.45 (0.34–0.60), <0.0001 4.6 60 with baseline AFP Placebo 95 7.3 1.6 1.1 39 400 ng/mL Cabozantinib (16) TKI c-Met, VEGFR-2, c-Kit, III 2nd line or 3rd line Cabozantinib 470 10.2 0.76 (0.63–0.92), 0.0049 5.2 0.44 (0.36–0.52), 0.001 4 64 RET, FLT-3, TIE2, Axl Placebo 237 8.0 1.9 0.4 33 Abbreviations: AFP, a-fetoprotein; CI, confidence interval; DCR, disease control rate; FGFR(1–4), fibroblast growth factor receptor; HR, hazard ratio; mAb, monoclonal antibody; mOS, median overall survival; mos, months; mPFS, median progression-free survival; N, number of subjects; ns, not significant; NR, not reported; ORR, objective response rate; PDGFR(-a,-b), platelet-derived growth factor receptors; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR(1–3), vascular endothelial growth factor receptor. aDisease-control rate was the percentage of patients who had a best-response rating of complete or partial response or stable disease that was maintained for at least 28 days after the first demonstration of that rating on independent radiologic review. bResponse based on modified RECIST criteria. cDefined as patients with complete response, partial response, or stable disease maintained for 6 weeks. dDefined as patients with complete response, partial response, or stable disease maintained for 12 weeks. eTime to progression. Clinical Cancer Research fPosthoc analysis of response using RECIST v1.1 ORR: 18.8% versus 6.5%; DCR: 72.8% versus 59.0%. Published OnlineFirst October 1, 2018; DOI: 10.1158/1078-0432.CCR-18-1254 Role of Angiogenesis in HCC (Table 1). Despite an initial breakthrough for the field, survival Cross-talk between FGF-2 and VEGF-A during initial phases of benefits observed with tyrosine kinase inhibitors (TKI) such as tumor growth induces neovascularization and further tumor sorafenib have been modest. Strategies for overcoming the high growth (33). FGF-2 and VEGF-A are associated with increased rate of acquired resistance to sorafenib, targeting other elements of capillarized sinusoids in HCC tumor angiogenesis (34), and angiogenic pathways alone or with other novel therapies, and the FGF stimulation modulates integrin expression that regulates investigation of biomarkers that may predict the efficacy of these endothelial cells in the microenvironment, thus altering cellular therapies are under development.
Load more

Recommended publications
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • Disruption of Fibroblast Growth Factor Signal
    Cancer Therapy: Preclinical Disruption of Fibroblast Growth Factor Signal Pathway Inhibits the Growth of Synovial Sarcomas: Potential Application of Signal Inhibitors to MolecularTarget Therapy Ta t s u y a I s hi b e , 1, 2 Tomitaka Nakayama,2 Ta k e s h i O k a m o t o, 1, 2 Tomoki Aoyama,1Koichi Nishijo,1, 2 Kotaro Roberts Shibata,1, 2 Ya s u ko Shim a ,1, 2 Satoshi Nagayama,3 Toyomasa Katagiri,4 Yusuke Nakamura, 4 Takashi Nakamura,2 andJunya Toguchida 1 Abstract Purpose: Synovial sarcoma is a soft tissue sarcoma, the growth regulatory mechanisms of which are unknown.We investigatedthe involvement of fibroblast growth factor (FGF) signals in synovial sarcoma andevaluatedthe therapeutic effect of inhibiting the FGF signal. Experimental Design:The expression of 22 FGF and4 FGF receptor (FGFR) genes in18prima- ry tumors andfive cell lines of synovial sarcoma were analyzedby reverse transcription-PCR. Effects of recombinant FGF2, FGF8, andFGF18 for the activation of mitogen-activatedprotein kinase (MAPK) andthe growth of synovial sarcoma cell lines were analyzed.Growth inhibitory effects of FGFR inhibitors on synovial sarcoma cell lines were investigated in vitro and in vivo. Results: Synovial sarcoma cell lines expressedmultiple FGF genes especially those expressed in neural tissues, among which FGF8 showedgrowth stimulatory effects in all synovial sarcoma cell lines. FGF signals in synovial sarcoma induced the phosphorylation of extracellular signal ^ regulatedkinase (ERK1/2) andp38MAPK but not c-Jun NH 2-terminal kinase. Disruption of the FGF signaling pathway in synovial sarcoma by specific inhibitors of FGFR causedcell cycle ar- rest leading to significant growth inhibition both in vitro and in vivo.Growthinhibitionbythe FGFR inhibitor was associatedwith a down-regulation of phosphorylatedERK1/2 but not p38MAPK, andan ERK kinase inhibitor also showedgrowth inhibitory effects for synovial sar- coma, indicating that the growth stimulatory effect of FGF was transmitted through the ERK1/2.
    [Show full text]
  • Different Fgfs Have Distinct Roles in Regulating Neurogenesis After Spinal Cord Injury in Zebrafish Yona Goldshmit1,2, Jean Kitty K
    Goldshmit et al. Neural Development (2018) 13:24 https://doi.org/10.1186/s13064-018-0122-9 RESEARCHARTICLE Open Access Different Fgfs have distinct roles in regulating neurogenesis after spinal cord injury in zebrafish Yona Goldshmit1,2, Jean Kitty K. Y. Tang1, Ashley L. Siegel1, Phong D. Nguyen1, Jan Kaslin1, Peter D. Currie1 and Patricia R. Jusuf1,3* Abstract Background: Despite conserved developmental processes and organization of the vertebrate central nervous system, only some vertebrates including zebrafish can efficiently regenerate neural damage including after spinal cord injury. The mammalian spinal cord shows very limited regeneration and neurogenesis, resulting in permanent life-long functional impairment. Therefore, there is an urgent need to identify the cellular and molecular mechanisms that can drive efficient vertebrate neurogenesis following injury. A key pathway implicated in zebrafish neurogenesis is fibroblast growth factor signaling. Methods: In the present study we investigated the roles of distinctfibroblastgrowthfactormembersandtheir receptors in facilitating different aspects of neural development and regeneration at different timepoints following spinal cord injury. After spinal cord injury in adults and during larval development, loss and/or gain of Fgf signaling was combined with immunohistochemistry, in situ hybridization and transgenes marking motor neuron populations in in vivo zebrafish and in vitro mammalian PC12 cell culture models. Results: Fgf3 drives neurogenesis of Islet1 expressing motor neuron subtypes and mediate axonogenesis in cMet expressing motor neuron subtypes. We also demonstrate that the role of Fgf members are not necessarily simple recapitulating development. During development Fgf2, Fgf3 and Fgf8 mediate neurogenesis of Islet1 expressing neurons and neuronal sprouting of both, Islet1 and cMet expressing motor neurons.
    [Show full text]
  • The Biology of Hepatocellular Carcinoma: Implications for Genomic and Immune Therapies Galina Khemlina1,4*, Sadakatsu Ikeda2,3 and Razelle Kurzrock2
    Khemlina et al. Molecular Cancer (2017) 16:149 DOI 10.1186/s12943-017-0712-x REVIEW Open Access The biology of Hepatocellular carcinoma: implications for genomic and immune therapies Galina Khemlina1,4*, Sadakatsu Ikeda2,3 and Razelle Kurzrock2 Abstract Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a leading cause of cancer-related death worldwide. It is highly refractory to most systemic therapies. Recently, significant progress has been made in uncovering genomic alterations in HCC, including potentially targetable aberrations. The most common molecular anomalies in this malignancy are mutations in the TERT promoter, TP53, CTNNB1, AXIN1, ARID1A, CDKN2A and CCND1 genes. PTEN loss at the protein level is also frequent. Genomic portfolios stratify by risk factors as follows: (i) CTNNB1 with alcoholic cirrhosis; and (ii) TP53 with hepatitis B virus-induced cirrhosis. Activating mutations in CTNNB1 and inactivating mutations in AXIN1 both activate WNT signaling. Alterations in this pathway, as well as in TP53 and the cell cycle machinery, and in the PI3K/Akt/mTor axis (the latter activated in the presence of PTEN loss), as well as aberrant angiogenesis and epigenetic anomalies, appear to be major events in HCC. Many of these abnormalities may be pharmacologically tractable. Immunotherapy with checkpoint inhibitors is also emerging as an important treatment option. Indeed, 82% of patients express PD-L1 (immunohistochemistry) and response rates to anti-PD-1 treatment are about 19%, and include about 5% complete remissions as well as durable benefit in some patients. Biomarker-matched trials are still limited in this disease, and many of the genomic alterations in HCC remain challenging to target.
    [Show full text]
  • Figure S1. Reverse Transcription‑Quantitative PCR Analysis of ETV5 Mrna Expression Levels in Parental and ETV5 Stable Transfectants
    Figure S1. Reverse transcription‑quantitative PCR analysis of ETV5 mRNA expression levels in parental and ETV5 stable transfectants. (A) Hec1a and Hec1a‑ETV5 EC cell lines; (B) Ishikawa and Ishikawa‑ETV5 EC cell lines. **P<0.005, unpaired Student's t‑test. EC, endometrial cancer; ETV5, ETS variant transcription factor 5. Figure S2. Survival analysis of sample clusters 1‑4. Kaplan Meier graphs for (A) recurrence‑free and (B) overall survival. Survival curves were constructed using the Kaplan‑Meier method, and differences between sample cluster curves were analyzed by log‑rank test. Figure S3. ROC analysis of hub genes. For each gene, ROC curve (left) and mRNA expression levels (right) in control (n=35) and tumor (n=545) samples from The Cancer Genome Atlas Uterine Corpus Endometrioid Cancer cohort are shown. mRNA levels are expressed as Log2(x+1), where ‘x’ is the RSEM normalized expression value. ROC, receiver operating characteristic. Table SI. Clinicopathological characteristics of the GSE17025 dataset. Characteristic n % Atrophic endometrium 12 (postmenopausal) (Control group) Tumor stage I 91 100 Histology Endometrioid adenocarcinoma 79 86.81 Papillary serous 12 13.19 Histological grade Grade 1 30 32.97 Grade 2 36 39.56 Grade 3 25 27.47 Myometrial invasiona Superficial (<50%) 67 74.44 Deep (>50%) 23 25.56 aMyometrial invasion information was available for 90 of 91 tumor samples. Table SII. Clinicopathological characteristics of The Cancer Genome Atlas Uterine Corpus Endometrioid Cancer dataset. Characteristic n % Solid tissue normal 16 Tumor samples Stagea I 226 68.278 II 19 5.740 III 70 21.148 IV 16 4.834 Histology Endometrioid 271 81.381 Mixed 10 3.003 Serous 52 15.616 Histological grade Grade 1 78 23.423 Grade 2 91 27.327 Grade 3 164 49.249 Molecular subtypeb POLE 17 7.328 MSI 65 28.017 CN Low 90 38.793 CN High 60 25.862 CN, copy number; MSI, microsatellite instability; POLE, DNA polymerase ε.
    [Show full text]
  • FGF/FGFR-2(Iiib) Signaling Is Essential for Inner Ear Morphogenesis
    The Journal of Neuroscience, August 15, 2000, 20(16):6125–6134 FGF/FGFR-2(IIIb) Signaling Is Essential for Inner Ear Morphogenesis Ulla Pirvola,1,2 Bradley Spencer-Dene,3 Liang Xing-Qun,1,2 Pa¨ ivi Kettunen,1 Irma Thesleff,1 Bernd Fritzsch,4 Clive Dickson,3 and Jukka Ylikoski1,2 1Institute of Biotechnology and 2Department of Otorhinolaryngology, University of Helsinki, 00014 Helsinki, Finland, 3Viral Carcinogenesis Laboratory, Imperial Cancer Research Fund, London, WC2A 3PX, United Kingdom, and 4Department of Biomedical Sciences, Creighton University, Omaha, Nebraska 68178-0405 Interactions between FGF10 and the IIIb isoform of FGFR-2 paracrine signals that operate within the epithelium. Expression appear to be crucial for the induction and growth of several of FGF10 mRNA partly overlapped with FGF3 mRNA in the organs, particularly those that involve budding morphogenesis. sensory regions, suggesting that they may form parallel signaling We determined their expression patterns in the inner ear and pathways within the otic epithelium. In addition, hindbrain- analyzed the inner ear phenotype of mice specifically deleted for derived FGF3 might regulate otocyst morphogenesis through the IIIb isoform of FGFR-2. FGF10 and FGFR-2(IIIb) mRNAs FGFR-2(IIIb). Targeted deletion of FGFR-2(IIIb) resulted in severe showed distinct, largely nonoverlapping expression patterns in dysgenesis of the cochleovestibular membraneous labyrinth, the undifferentiated otic epithelium. Subsequently, FGF10 mRNA caused by a failure in morphogenesis at the otocyst stage. In became confined to the presumptive cochlear and vestibular addition to the nonsensory epithelium, sensory patches and the sensory epithelia and to the neuronal precursors and neurons. cochleovestibular ganglion remained at a rudimentary stage.
    [Show full text]
  • Epigenetic Regulation of Processes Related to High Level of Fibroblast Growth Factor 21 in Obese Subjects
    G C A T T A C G G C A T genes Article Epigenetic Regulation of Processes Related to High Level of Fibroblast Growth Factor 21 in Obese Subjects Teresa Płatek 1,*, Anna Polus 1, Joanna Góralska 1, Urszula Ra´zny 1 , Agnieszka Dziewo ´nska 1, Agnieszka Micek 2 , Aldona Dembi ´nska-Kie´c 1, Bogdan Solnica 1 and Małgorzata Malczewska-Malec 1 1 Department of Clinical Biochemistry, Jagiellonian University Medical College, 15a Kopernika Street, 31-501 Krakow, Poland; [email protected] (A.P.); [email protected] (J.G.); [email protected] (U.R.); [email protected] (A.D.); [email protected] (A.D.-K.); [email protected] (B.S.); [email protected] (M.M.-M.) 2 Department of Nursing Management and Epidemiology Nursing, Faculty of Health Sciences, Jagiellonian University Medical College, 25 Kopernika Street, 31-501 Krakow, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-12-424-87-87 Abstract: We hypothesised that epigenetics may play an important role in mediating fibroblast growth factor 21 (FGF21) resistance in obesity. We aimed to evaluate DNA methylation changes and miRNA pattern in obese subjects associated with high serum FGF21 levels. The study included 136 participants with BMI 27–45 kg/m2. Fasting FGF21, glucose, insulin, GIP, lipids, adipokines, miokines and cytokines were measured and compared in high serum FGF21 (n = 68) group to low Citation: Płatek, T.; Polus, A.; FGF21 (n = 68) group. Human DNA Methylation Microarrays were analysed in leukocytes from Góralska, J.; Ra´zny, U.; each group (n = 16).
    [Show full text]
  • FGF/FGFR Signaling in Health and Disease
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN FGF/FGFR signaling in health and disease Yangli Xie1, Nan Su1, Jing Yang1, Qiaoyan Tan1, Shuo Huang 1, Min Jin1, Zhenhong Ni1, Bin Zhang1, Dali Zhang1, Fengtao Luo1, Hangang Chen1, Xianding Sun1, Jian Q. Feng2, Huabing Qi1 and Lin Chen 1 Growing evidences suggest that the fibroblast growth factor/FGF receptor (FGF/FGFR) signaling has crucial roles in a multitude of processes during embryonic development and adult homeostasis by regulating cellular lineage commitment, differentiation, proliferation, and apoptosis of various types of cells. In this review, we provide a comprehensive overview of the current understanding of FGF signaling and its roles in organ development, injury repair, and the pathophysiology of spectrum of diseases, which is a consequence of FGF signaling dysregulation, including cancers and chronic kidney disease (CKD). In this context, the agonists and antagonists for FGF-FGFRs might have therapeutic benefits in multiple systems. Signal Transduction and Targeted Therapy (2020) 5:181; https://doi.org/10.1038/s41392-020-00222-7 INTRODUCTION OF THE FGF/FGFR SIGNALING The binding of FGFs to the inactive monomeric FGFRs will Fibroblast growth factors (FGFs) are broad-spectrum mitogens and trigger the conformational changes of FGFRs, resulting in 1234567890();,: regulate a wide range of cellular functions, including migration, dimerization and activation of the cytosolic tyrosine kinases by proliferation, differentiation, and survival. It is well documented phosphorylating the tyrosine residues within the cytosolic tail of that FGF signaling plays essential roles in development, metabo- FGFRs.4 Then, the phosphorylated tyrosine residues serve as the lism, and tissue homeostasis.
    [Show full text]
  • RT² Profiler PCR Array (96-Well Format and 384-Well [4 X 96] Format)
    RT² Profiler PCR Array (96-Well Format and 384-Well [4 x 96] Format) Rat Growth Factors Cat. no. 330231 PARN-041ZA For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 5700, 7000, 7300, 7500, Format A 7700, 7900HT, ViiA™ 7 (96-well block); Bio-Rad® models iCycler®, iQ™5, MyiQ™, MyiQ2; Bio-Rad/MJ Research Chromo4™; Eppendorf® Mastercycler® ep realplex models 2, 2s, 4, 4s; Stratagene® models Mx3005P®, Mx3000P®; Takara TP-800 RT² Profiler PCR Array, Applied Biosystems models 7500 (Fast block), 7900HT (Fast Format C block), StepOnePlus™, ViiA 7 (Fast block) RT² Profiler PCR Array, Bio-Rad CFX96™; Bio-Rad/MJ Research models DNA Format D Engine Opticon®, DNA Engine Opticon 2; Stratagene Mx4000® RT² Profiler PCR Array, Applied Biosystems models 7900HT (384-well block), ViiA 7 Format E (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (96-well block) Format F RT² Profiler PCR Array, Roche LightCycler 480 (384-well block) Format G RT² Profiler PCR Array, Fluidigm® BioMark™ Format H Sample & Assay Technologies Description The Rat Growth Factors RT² Profiler PCR Array profiles the expression of 84 genes related to growth factors. Growth factors play a vital role in various normal biological processes such as embryogenesis, wound healing and inflammation. This array contains angiogenic growth factors and regulators of apoptosis. Genes involved in cell differentiation are included as well. Also represented are genes related to embryonic development as well as genes involved in tissue-specific development. Using real-time PCR, you can easily and reliably analyze expression of a focused panel of genes related to the growth factors with this array.
    [Show full text]
  • The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor
    International Journal of Molecular Sciences Review The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor Annalisa Astolfi 1 , Maria Abbondanza Pantaleo 2,*, Valentina Indio 3 , Milena Urbini 4 and Margherita Nannini 5 1 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, 44121 Ferrara, Italy; annalisa.astolfi@unife.it 2 Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy 3 “Giorgio Prodi” Cancer Research Center, University of Bologna, 40138 Bologna, Italy; [email protected] 4 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola, Italy; [email protected] 5 Medical Oncology Unit, S.Orsola-Malpighi University Hospital, 40138 Bologna, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-051-214-4043; Fax: +39-051-349-655 Received: 10 April 2020; Accepted: 4 May 2020; Published: 7 May 2020 Abstract: Gastrointestinal stromal tumors (GIST) are rare neoplasms of mesenchymal origin arising in the gastrointestinal tract. The vast majority are characterized by mutually exclusive activating mutations in KIT or Platelet-derived growth factor alpha (PDGFRA) receptors, or less frequently by succinate dehydrogenase complex (SDH) or NF1 inactivation, with very rare cases harboring mutant BRAF or RAS alleles. Approximately 5% of GISTs lack any of such mutations and are called quadruple wild-type (WT) GISTs. Recently, deregulated Fibroblast Growth Factor (FGF)/FGF-receptor (FGFR) signaling emerged as a relevant pathway driving oncogenic activity in different molecular subgroups of GISTs. This review summarizes all the current evidences supporting the key role of the FGF/FGFR pathway activation in GISTs, whereby either activating mutations, oncogenic gene fusions, or autocrine/paracrine signaling have been detected in quadruple WT, SDH-deficient, or KIT-mutant GISTs.
    [Show full text]
  • Increased Levels of Fibroblast Growth Factor-Like Activity in Urine from Patients with Bladder Or Kidney Cancer1
    [CANCER RESEARCH 48, 2083-20S8, April IS, 1988] Increased Levels of Fibroblast Growth Factor-like Activity in Urine from Patients with Bladder or Kidney Cancer1 Gerald W. Chodak,2 Verne Hospelhorn, Sheila M. Judge, Ruth May forth, Hartmut Koeppen, and Joachim Sasse Departments of Surgery/Urology [G. W. C., V. H., S. M. ]., and R. M.¡and Pathology [H. K.J, The University of Chicago and the Pritzker School of Medicine, Chicago, Illinois 60637, and the Department of Surgical Research fJ. SJ, Children's Hospital Medical Center, Boston, Massachusetts 021 IS ABSTRACT factors may be useful as a marker for this disease. In this paper, we show that men with bladder or renal tumors can be distin Growth factor activity was partially purified from human renal tumors guished from normal men by the presence of higher levels of a and a human bladder cancer cell line by heparin-Sepharose chromatog- heparin-binding, angiogenic-like growth factor in their urine raphy. This activity stimulated bovine capillary endothelial cell prolifer ation and DNA synthesis in BALB/c 3T3 cells. Partially purified growth which is similar to basic fibroblast growth factor. factor preparations from these tumors contained a protein with an ap proximate molecular weight of 17,000 which was recognized by a poly- MATERIALS AND METHODS clonal antiserum raised against a peptide fragment of basic fibroblast growth factor (FGF). This growth factor activity appears to be related to Preparation of Tumor Extracts basic fibroblast growth factor. Measurement of FGF-like activity in 50 urine samples from 32 adult Fresh tumor tissue was obtained through the Department of Pathol males showed that 55% (6 of 11 ) of the urine samples from patients with ogy at the University of Chicago from patients undergoing a radical bladder cancer and 100% (7 of 7) of the urine samples from patients with nephrectomy for adenocarcinoma of the kidney.
    [Show full text]
  • Basic Fibroblast Growth Factor (Fgf2) Is Necessary for Cell Proliferation and Neurogenesis in the Developing Cerebral Cortex
    The Journal of Neuroscience, July 1, 2000, 20(13):5012–5023 Basic Fibroblast Growth Factor (Fgf2) Is Necessary for Cell Proliferation and Neurogenesis in the Developing Cerebral Cortex Rossana Raballo,1 Julianne Rhee,1 Richard Lyn-Cook,1 James F. Leckman,1 Michael L. Schwartz,2 and Flora M. Vaccarino1,2 1Child Study Center and 2Section of Neurobiology, Yale University, New Haven, Connecticut 06520 Little is known about regionally specific signals that control the of neurogenesis. Despite this reduction, the degree of apopto- number of neuronal progenitor cells in vivo. We have previously sis within the PVE is not changed in the Fgf2 knockouts. shown that the germline mutation of the basic fibroblast growth Cortical neuron number was decreased by 45% in Fgf2 knock- factor (Fgf2) gene results in a reduction in the number of cortical out mice by the end of neurogenesis, whereas the number of neurons in the adult. We show here that Fgf2 is expressed in the neurons in the basal ganglia was unaffected. Microscopically, pseudostratified ventricular epithelium (PVE) in a dorsoventral the frontal cerebral cortex of neonatal Fgf2 null mutant mice gradient and that Fgf2 and its receptor, Fgfr-1, are downregu- lacked large neurons in deep cortical layers. We suggest that lated by mid to late stages of neurogenesis. In Fgf2 knockout Fgf2 is required for the generation of a specific class of cortical mice, the volume and cell number of the dorsal PVE (the neurons arising from the dorsal PVE. cerebral cortical anlage) are substantially smaller, whereas the Key words: fibroblast growth factor; Fgf2; knockout; null volume of the basal PVE is unchanged.
    [Show full text]